The abstract is read at the publisher; the summary is JClub's.
A clinically relevant AAV8-delivered HsPEX1 subretinal gene therapy improves retinal structure and function in a murine mild Zellweger spectrum disorder model, with durability through 6 months.
- Why it matters: Zellweger spectrum disorder lacks proven targeted disease-modifying treatments, and it is unclear whether restoring peroxisome function locally in the retina can slow degeneration.
- What they did: The study performed a dose-range evaluation of redesigned AAV8-delivered HsPEX1 subretinal gene augmentation in mice with mild ZSD homozygous for the murine PEX1-p.[Gly844Asp] equivalent, using expanded functional, structural, inflammatory, and metabolite outcomes.
- The result: Treated eyes showed significant gains in functional vision, retinal electrophysiology, photoreceptor structure, retinal pigment epithelium integrity, subretinal inflammation, and peroxisomal metabolites, maintained to 6 months after a single subretinal injection.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.